| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The primary targets of Euphorbia factor L8 are not well-characterized. As a diterpene from Euphorbia species, it may share biological activities with other Euphorbia diterpenes, which often exhibit cytotoxic, anti-inflammatory, or antimicrobial properties. The compound's complex structure with a nicotinoyloxy group and multiple acetates suggests potential for interactions with various biological targets. However, specific molecular targets have not been identified in the published literature.
|
|---|---|
| ln Vitro |
In vitro activity data for Euphorbia factor L8 are limited in the published literature. The compound has been primarily characterized as a natural product from Euphorbia lathyris and Morinda citrifolia seeds. As a diterpenoid, it may exhibit cytotoxic activity against cancer cell lines or anti-inflammatory effects, similar to other Euphorbia diterpenes. However, detailed in vitro activity data including IC₅₀ values are not extensively published. Further studies are needed to characterize its biological activities.
|
| ln Vivo |
In vivo activity data for Euphorbia factor L8 are not available in the published literature. The compound has been primarily characterized as a natural product isolate. No in vivo pharmacological studies have been reported for this compound. Further research is needed to evaluate its potential therapeutic applications in animal models. The compound's natural occurrence in Euphorbia seeds suggests it may have ecological or physiological roles in the source plant.
|
| Enzyme Assay |
In vitro assays for Euphorbia factor L8 are not extensively documented. As a diterpenoid natural product, potential assays could include cytotoxicity screening against cancer cell lines using MTT or SRB assays. The compound's structure can be confirmed by NMR and MS. Purity is typically assessed by HPLC with purity ≥97% available. Standard natural product screening assays may be used to evaluate its biological activities.
|
| Cell Assay |
In vitro cellular assays for Euphorbia factor L8 are not extensively documented. As a diterpenoid from Euphorbia species, potential cellular assays could include evaluation of cytotoxicity in cancer cell lines, anti-inflammatory activity in immune cells, or effects on cellular signaling pathways. The compound is typically handled as a powder and may be soluble in appropriate organic solvents for cell culture applications.
|
| Animal Protocol |
In vivo animal experiments for Euphorbia factor L8 have not been reported in the published literature. The compound has been studied primarily as a natural product isolate. No animal studies have been conducted to evaluate its pharmacological effects, toxicity, or pharmacokinetics. Further research would be required to investigate its potential therapeutic applications in vivo.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Euphorbia factor L8 have not been characterized. The compound has a molecular weight of 523.62 g/mol and molecular formula C₃₀H₃₇NO₇. As a lipophilic diterpenoid with multiple acetate groups and a nicotinoyloxy moiety, it is expected to have moderate to high lipophilicity and good membrane permeability. The compound is typically stored as a powder under recommended conditions.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Euphorbia factor L8 is not extensively documented. As a diterpene from Euphorbia species, its toxicity profile may be similar to other Euphorbia diterpenes, which can exhibit irritant or toxic properties at high concentrations. Comprehensive toxicological evaluations including acute toxicity, genotoxicity, and repeated-dose studies have not been reported. Standard laboratory safety precautions should be followed.
|
| References | |
| Additional Infomation |
Euphorbia factor L8 (CAS# 218916-53-1, molecular formula C₃₀H₃₇NO₇, molecular weight 523.62) is a diterpene from Euphorbia lathyris and Morinda citrifolia seeds. Also known as 大戟因子L8 (Chinese). No clinical trials or regulatory approvals have been identified. Purity: ≥97%.
|
| Molecular Formula |
C30H37NO7
|
|---|---|
| Molecular Weight |
523.617289304733
|
| Exact Mass |
523.257
|
| CAS # |
218916-53-1
|
| PubChem CID |
10697375
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
600.7±55.0 °C at 760 mmHg
|
| Flash Point |
317.1±31.5 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.557
|
| LogP |
5.94
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
38
|
| Complexity |
1050
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C=C1CC[C@H]2[C@@H](C=C(C)C(=O)[C@]3(C[C@H](C)[C@@H]([C@@H]3[C@H]1OC(=O)C)OC(=O)C4=CN=CC=C4)OC(=O)C)C2(C)C
|
| InChi Key |
PJHBZROILRCFRB-DJYFZMDUSA-N
|
| InChi Code |
InChI=1S/C30H37NO7/c1-16-10-11-22-23(29(22,6)7)13-17(2)27(34)30(38-20(5)33)14-18(3)26(24(30)25(16)36-19(4)32)37-28(35)21-9-8-12-31-15-21/h8-9,12-13,15,18,22-26H,1,10-11,14H2,2-7H3/b17-13-/t18-,22-,23+,24-,25-,26-,30+/m0/s1
|
| Chemical Name |
[(1R,3Z,5R,7S,11R,12R,13S,14S)-1,11-diacetyloxy-3,6,6,14-tetramethyl-10-methylidene-2-oxo-13-tricyclo[10.3.0.05,7]pentadec-3-enyl] pyridine-3-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9098 mL | 9.5489 mL | 19.0978 mL | |
| 5 mM | 0.3820 mL | 1.9098 mL | 3.8196 mL | |
| 10 mM | 0.1910 mL | 0.9549 mL | 1.9098 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
